ACR Convergence

An official publication of the ACR and the ARP serving rheumatologists and rheumatolgy professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • ACR Open Rheumatology
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout and Crystalline Arthritis

  • Gout Resource Center

    Earlier this year, the ACR released a new guideline for the management of gout, leaving some rheumatologists unsure what to recommend to their patients. Clearing up the confusion is one aim of the session, Evidence-Based Guidance for Optimizing Gout Management. Learn what the experts recommend and explore our coverage of additional gout information presented at ACR Convergence 2020, plus our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout.


    VIEW

3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout

Arthritis Care & Research  |  August 13, 2023

Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…

Pegloticase Plus Methotrexate Effective for Uncontrolled Gout

Glen Rodman  |  August 8, 2023

The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.

Treat to Target Lowers the Risk of Fracture in Patients with Gout

Arthritis & Rheumatology  |  July 26, 2023

Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.

Tigulixostat Promising for Patients with Gout & Hyperuricemia

Arthritis & Rheumatology  |  June 28, 2023

In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.

Point-of-Care Uric Acid Testing

Samantha C. Shapiro, MD  |  March 1, 2023

In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research  |  February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Gout & Excess Risk of Severe SARS-CoV-2 Infection

Arthritis & Rheumatology  |  January 3, 2023

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status.

Pseudo-What? Exploring the Classification Criteria Development Process for CPPD

Jason Liebowitz, MD  |  December 12, 2022

PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation. An ACR Convergence 2022 session sought to update the audience on the progress to date in developing…

Rheumatic Disease Research in Indigenous Populations

Samantha C. Shapiro, MD  |  December 2, 2022

This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.

Considering Benzbromarone as First-Line Therapy for Gout

Arthritis & Rheumatology  |  December 1, 2022

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.

  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2000-2023 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences